Clinical Lymphoma and Myeloma This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
CONCLUSION: Treated progression of DLBCL increases adjusted PPPM costs by over $8000 compared with no progression.PMID:37704514 | DOI:10.1016/j.clml.2023.08.005 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 13, 2023 Category: Cancer & Oncology Authors: John M Burke Anthony Masaquel Rongrong Wang Farah Hossain Jia Li Summera Qiheng Zhou Carmen D Ng Matthew Matasar Source Type: research

Descriptive Analysis and Factors Influencing Survival in Patients With Primary Cutaneous Gamma-Delta T Cell Lymphoma. A Retrospective National Cancer Database Study
CONCLUSION: Socioeconomic disparities significantly impact access to healthcare and are of particular importance in rare lymphomas.PMID:37690902 | DOI:10.1016/j.clml.2023.08.015 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 10, 2023 Category: Cancer & Oncology Authors: Prashanth Ashok Kumar Abirami Sivapiragasam Dongliang Wang Danning Huang Teresa Gentile Source Type: research

Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results
CONCLUSIONS: Significant disparities in cancer care exist among geographic locations. Geographic differences in survival appear more prominent when highly effective therapies are available.PMID:37690903 | DOI:10.1016/j.clml.2023.08.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 10, 2023 Category: Cancer & Oncology Authors: Koji Sasaki Kiyomi Morita Hagop Kantarjian Guillermo Garcia-Manero Elias Jabbour Farhad Ravandi Marina Konopleva Gautam Borthakur William Wierda Naval Daver Koichi Takahashi Courtney DiNardo Guillermo Montalban Bravo Ghayas C Issa Sherry A Pierce Kelly A Source Type: research

The Impact of CD34 + Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma
CONCLUSION: Although bortezomib is not considered stem-cell toxic, it may be associated with lower stem cell collection yields. Bortezomib's efficacy at induction may partially explain the improved outcomes, however, other factors may be involved, and are discussed. We can conclude that with our large cohort and long follow-up, high stem-cell mobilization does not appear to predict for a long-term survival advantage.PMID:37689547 | DOI:10.1016/j.clml.2023.07.014 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 9, 2023 Category: Cancer & Oncology Authors: Eyal Lebel Katherine Lajkosz Esther Masih-Khan Donna Reece Suzanne Trudel Rodger Tiedemann Anca Prica Vishal Kukreti Christine Chen Source Type: research

A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure
CONCLUSION: Pomalidomide-based combination regimens were effective in patients with RRMM previously treated with lenalidomide and tended to be associated with better outcomes when used earlier in the treatment pathway. A drug class switch may not always be necessary when making treatment decisions for patients with RRMM for whom the benefits of lenalidomide have been exhausted, although this must be supported by comparative studies.PMID:37684184 | DOI:10.1016/j.clml.2023.07.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 8, 2023 Category: Cancer & Oncology Authors: Faith E Davies Xavier Leleu Prisca Vogel Sujith Dhanasiri Pauline Le Nouveau Katja Weisel Source Type: research

Loss of CD34 + Cells and Effect of the Number of Viable Cryopreserved CD34 + Cells in the Infused Blood Grafts on Hematologic Recovery, Progression-Free Survival and Overall Survival in NHL Patients After Autologous Stem Cell Transplantation
CONCLUSIONS: G-CSF type used in mobilization and mobilization capacity were found to correlate with viable CD34+ cell loss during processing and storage. Most importantly, low infused viable CD34+ cell count did not seem to impact on PFS or OS.PMID:37684185 | DOI:10.1016/j.clml.2023.08.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 8, 2023 Category: Cancer & Oncology Authors: Anu Partanen Antti Turunen Jaakko Valtola Marja Py örälä Outi Kuittinen Hanne Kuitunen Kaija Vasala Karri Penttil ä Taru Kuittinen Pentti M äntymaa Jukka Pelkonen Esa Jantunen Ville Varmavuo Source Type: research

SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors
Clin Lymphoma Myeloma Leuk. 2023 Aug 14:S2152-2650(23)00258-6. doi: 10.1016/j.clml.2023.08.011. Online ahead of print.ABSTRACTMantle cell lymphoma is a challenging subtype of B-cell non-Hodgkin lymphoma treat characterized by its aggressive nature and propensity for relapse or refractory (R/R) disease for many patients. The introduction of Bruton's tyrosine kinase inhibitors has significantly improved the outcomes for patients with R/R MCL, but a considerable proportion of patients eventually experience disease progression or develop resistance to these agents. In recent years, immunotherapeutic approaches have emerged as ...
Source: Clinical Lymphoma and Myeloma - September 4, 2023 Category: Cancer & Oncology Authors: Rahul K Nayak Drew Gerber Chen Zhang Jonathon B Cohen Source Type: research